Beijing Novartis Pharmaceuticals Limited, founded in 1987, is the earliest and largest foreign pharmaceutical enterprise established in Beijing. Over the past twenty years, Beijing Novartis Pharma has achieved remarkable results, with operations in more than 260 cities across China. In the past few years, Beijing Novartis Pharma has grown at an average rate of more than 20%, making it one of the highest-growth companies in the Novartis Group and one of the top multinational pharmaceutical companies.
Beijing Novartis Pharma's products in China cover 9 major fields including cardiovascular, endocrine, anti-infective, oncology, transplantation and immunity, rheumatism and pain, bone metabolism, ophthalmology, central nervous system, etc., with more than 30 international first-class innovative products. 2009 Beijing Novartis Pharma launched 5 innovative products in various fields: Migulinda®(osteoporosis), Mif&... reg; (transplantation), Lysol® extended-release tablets (lipid-lowering), Trelle® oral suspension (anti-epileptic), and Estrin® (anti-hypertensive), providing more effective and safe drug choices for a wide range of patients. 2010, the company will launch two innovative products in the cardiovascular field: the world's first ARB/CCB single tablet compound preparation Bebot® and the only successfully developed new class of antihypertensive drugs - the direct renin inhibitor Rexolix. Beijing Novartis attaches great importance to customer needs and is committed to improving customer satisfaction. According to the "2009 Customer Satisfaction Survey" conducted by TNS Market Research, Beijing Novartis Pharma has been ranked first in the customer satisfaction survey for five consecutive years. On this basis, in 2009, Beijing Novartis further took "patient-oriented" as the new focus of the company's cultural construction, providing the best quality service for patients, and improving the quality of life of patients by fully understanding their experiences and relieving their pains through a variety of activities of continuous innovation.
2010 is a year for Beijing Novartis to seize the opportunity and create a brilliant future. The company launched the "Ambition Plan" to optimize its organizational structure, rationally allocate resources, and stay close to local needs to provide quality services to more patients and customers.
Novartis Changping Plant is located in Beijing Changping Science and Technology Park, with a total investment of 50 million US dollars, covering an area of 28,000 square meters, with international GMP standardized clean plant and a full set of advanced production equipment and facilities imported from Europe, with oral solid dosage (tablets, capsules) production line, ointment production line, equipped with aluminum aluminum, aluminum-plastic packaging production line, equipped with automatic purified water preparation facility and The plant is equipped with fully automated purified water preparation facilities and bio-turntable sewage treatment facilities, with an annual production capacity of 2 billion tablets (capsules) and 12 million emulsions. As one of the standardized GMP factories of Novartis, the factory accepts the technology and quality management of Novartis Global Pharmaceutical Technology Department in Switzerland.